Titel

Merkliste
1 Ergebnisse

The Expiry of Humira ® Market Exclusivity and the Entry of ..:

Moorkens, Evelien ; Godman, Brian ; Huys, Isabelle...
Moorkens , E , Godman , B , Huys , I , Hoxha , I , Malaj , A , Keuerleber , S , Stockinger , S , Mörtenhuber , S , Dimitrova , M , Tachkov , K , Vončina , L , Palčevski , V V , Achniotou , G , Slabý , J , Popelková , L , Kohoutová , K , Bartels , D , Laius , O , Martikainen , J E , Selke , G W , Kourafalos , V , Magnússon , E , Einarsdóttir , R , Adams , R , Joppi , R , Allocati , E , Jakupi , A , Viksna , A , Greičiūtė-Kuprijanov , I , Vella Bonanno , P , Suttorp , V , Melien , Ø , Plisko , R , Mardare , I , Meshkov , D , Novakovic , T , Fürst , J , Zara , C , Marković-Peković , V , Grubiša , N , Befrits , G , Puckett , R & Vulto , A G 2021 , ' The Expiry of Humira ® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe : An Overview of Pricing and National Policy Measures ' , Frontiers in Pharmacology , vol. 11 , 591134 . https://doi.org/10.3389/fphar.2020.591134. , 2021

Link: https://pure.eur.nl/en/publications/5c549ede-897d-4232..

RT Journal
T1 <Title>The Expiry of Humira ® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe:An Overview of Pricing and National Policy Measures</Title>

UL https://suche.suub.uni-bremen.de/peid=base-fturottercrispub:oai:pure.eur.nl:publications_5c549ede-897d-4232-87f5-4e69f58066bc&Exemplar=1&LAN=DE
				
A1 Moorkens, Evelien
A1 Godman, Brian
A1 Huys, Isabelle
A1 Hoxha, Iris
A1 Malaj, Admir
A1 Keuerleber, Simon
A1 Stockinger, Silvia
A1 Mörtenhuber, Sarah
A1 Dimitrova, Maria
A1 Tachkov, Konstantin
A1 Vončina, Luka
A1 Palčevski, Vera Vlahović
A1 Achniotou, Gnosia
A1 Slabý, Juraj
A1 Popelková, Leona
A1 Kohoutová, Kateřina
A1 Bartels, Dorthe
A1 Laius, Ott
A1 Martikainen, Jaana E
A1 Selke, Gisbert W
A1 Kourafalos, Vasileios
A1 Magnússon, Einar
A1 Einarsdóttir, Rannveig
A1 Adams, Roisín
A1 Joppi, Roberta
A1 Allocati, Eleonora
A1 Jakupi, Arianit
A1 Viksna, Anita
A1 Greičiūtė-Kuprijanov, Ieva
A1 Vella Bonanno, Patricia
A1 Suttorp, Vincent
A1 Melien, Øyvind
A1 Plisko, Robert
A1 Mardare, Ileana
A1 Meshkov, Dmitry
A1 Novakovic, Tanja
A1 Fürst, Jurij
A1 Zara, Corinne
A1 Marković-Peković, Vanda
A1 Grubiša, Nataša
A1 Befrits, Gustaf
A1 Puckett, Robert
A1 Vulto, Arnold G
YR 2021
JF Moorkens , E , Godman , B , Huys , I , Hoxha , I , Malaj , A , Keuerleber , S , Stockinger , S , Mörtenhuber , S , Dimitrova , M , Tachkov , K , Vončina , L , Palčevski , V V , Achniotou , G , Slabý , J , Popelková , L , Kohoutová , K , Bartels , D , Laius , O , Martikainen , J E , Selke , G W , Kourafalos , V , Magnússon , E , Einarsdóttir , R , Adams , R , Joppi , R , Allocati , E , Jakupi , A , Viksna , A , Greičiūtė-Kuprijanov , I , Vella Bonanno , P , Suttorp , V , Melien , Ø , Plisko , R , Mardare , I , Meshkov , D , Novakovic , T , Fürst , J , Zara , C , Marković-Peković , V , Grubiša , N , Befrits , G , Puckett , R & Vulto , A G 2021 , ' The Expiry of Humira ® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe : An Overview of Pricing and National Policy Measures ' , Frontiers in Pharmacology , vol. 11 , 591134 . https://doi.org/10.3389/fphar.2020.591134
LK http://dx.doi.org/https://pure.eur.nl/en/publications/5c549ede-897d-4232-87f5-4e69f58066bc
DO https://pure.eur.nl/en/publications/5c549ede-897d-4232-87f5-4e69f58066bc
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)